Incidence_of_neuropathy_in_395_patients_with_ovarian_cancer_treated_with_or_without_cisplatin._In_two_consecutive_trials,_a_total_of_395_patients_with_ovarian_cancer_were_treated_with_a_combination_of_hexamethylmelamine,_cyclophosphamide,_methotrexate,_and_5-fluorouracil_chemotherapeutic_regimens_including_cisplatin_or_without_this_drug._With_respect_to_neurotoxicity,_387_patients_were_fully_eligible._The_median_follow-up_for_survival_was_45_months._Neurotoxicity_in_any_grade_of_severity_developed_in_47%_of_the_patients_treated_with_a_cisplatin-containing_regimen_and_in_25%_of_those_treated_with_the_non-cisplatin-containing_regimen._The_severity_of_neurotoxicity_was_much_higher,_however,_in_the_cisplatin-treated_patients._Neurotoxicity-free_survival_decreased_below_50%_at_cumulative_doses_of_cisplatin_between_500_and_600_mg/m2._No_additional_effect_of_hexamethylmelamine_on_the_incidence_or_severity_of_neurotoxicity_could_be_demonstrated._In_patients_who_survived_for_more_than_5_years,_the_incidence_of_cisplatin_neuropathy_was_61%._Prognostic_variables_(age,_International_Federation_of_Gynecology_and_Obstetrics_FIGO_stage,_performance_status,_and_others)_possibly_associated_with_high-risk_subgroups_could_not_be_identified._The_only_consistent_factor_correlated_with_neurotoxicity_was_the_total_dose_of_cisplatin_received.